 Connection
Paul Bunn to Precision Medicine
This is a "connection" page, showing publications Paul Bunn has written about Precision Medicine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.949 |
|
|
|
-
Bunn PA, Aisner DL. Broad-Based Molecular Testing for Lung Cancer: Precisely the Time for Precision. JAMA. 2018 08 07; 320(5):445-446.
Score: 0.480
-
Hirsch FR, Wynes MW, Gandara DR, Bunn PA. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010 Oct 15; 16(20):4909-11.
Score: 0.279
-
Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, J?nne PA, Mok TS, Wakelee HA, Pirker R, Mazi?res J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-638.
Score: 0.102
-
Bunn PA, Hirsch FR, Aisner DL. Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res. 2014 Apr 01; 20(7):1727-9.
Score: 0.088
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|